Approved by the U.S. Food and Drug Administration in 1994, Lamictal (lamotrigine) is used to treat patients who suffer from epilepsy. Specifically, the drug is used to control the occurrence of partial seizures, primary and secondary tonic-clonic seizures and the symptoms of Lennox-Gastaut syndrome. In 2003, the FDA also approved Lamictal for treatment of bipolar disorder.

Lamictal and Stevens Johnson Syndrome

Lamictal is associated with several side effects, including nausea, dizziness, vomiting and insomnia. Numerous patients who used the drug have also reported developing a serious allergic reaction known as Stevens Johnson Syndrome.

Patients who suffer from Stevens Johnson Syndrome typically experience flu-like symptoms before eventually developing a rash that can quickly spread. Stevens Johnson Syndrome (SJS) can cause blisters or lesions to form and many patients experience the most severe symptoms in the mucous membranes surrounding the eyes, nose, mouth and genital area.

As the condition progresses, the skin may eventually begin to slough off, causing the patient to take on a burned experience. Stevens Johnson Syndrome is also associated with another serious skin condition known as Toxic Epidermal Necrolysis (TEN). Patients with TEN experience widespread tissue death in the upper layers of skin and the condition is fatal in approximately 35% of all cases.

If you experience any unusual symptoms after taking Lamictal, it's important that you contact your doctor right away. Do not wait to seek treatment if you suspect you may have Stevens Johnson Syndrome, as this can have a significant impact on your recovery.

Legal Remedies for Lamictal SJS Sufferers

If you or a loved one developed Stevens Johnson Syndrome or Toxic Epidermal Necrolysis after taking Lamictal, you may be eligible to file a personal injury claim to receive compensation for your medical bills, lost wages and pain and suffering. Your first priority should be to contact an experienced Stevens Johnson Syndrome attorney to discuss your rights.